ABBOTT LABORATORIES WKN: 850103 ISIN: US0028241000 Kürzel: ABT Forum: Aktien Thema: Hauptdiskussion

Der Umsatz im Diagnostiksegment von Abbott sank im Vergleich zum Vorjahr um 2,5 % auf 2,46 Milliarden US-Dollar und verfehlte damit die Prognosen von 2,51 Milliarden US-Dollar. Der Umsatz im Segment Ernährung sank im Vergleich zum Vorjahr um 8,9 % auf 1,94 Milliarden US-Dollar, was auf geringere Absatzmengen und kürzlich vorgenommene strategische Preissenkungen zurückzuführen ist. Abbotts Geschäftsbereich für pädiatrische Ernährung, der Säuglingsnahrungen vertreibt, steht wegen Klagen unter Beobachtung, in denen behauptet wird, dass seine Spezialnahrung für Frühgeborene bei den Babys eine gefährliche Darmerkrankung namens nekrotisierende Enterokolitis verursacht habe. https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-misses-quarterly-revenue-estimates-weakness-diagnostics-segment-2026-01-22/

FY2026 Guidance: Adj. EPS: $5.55–$5.80 (vs. $5.15 est.) Organic Sales Growth: 6.5%–7.5%

Earnings - Q4/2025 Revenue: $11.46B ❌ vs. $11.78B est. EPS: $1.5 ✅ vs. $1.49 est. Abbott reports fourth-quarter 2025 results, highlighting margin expansion, double-digit earnings growth, and a productive new product pipeline that positions the company for accelerating growth in 2026. Management emphasizes organic sales growth as the core metric (excluding FX, ZonePerfect exits, and COVID-19 tests), with Nutrition soft in Q4 and Diagnostics mixed as launches aim to lift 2026 volumes. Guidance: full-year 2026 organic sales growth expected in the 6.5%–7.5% range; Abbott also declares its 408th consecutive quarterly dividend of $0.63 per share, payable Feb. 13, 2026.

Das sehe ich auch so, zu diesen Kursen muss man eigentlich nachkaufen

der dip ist apatestens in eibem monat vergessen vlt sogar diese woche

Buy and hold

Ist hier jemand investiert? Zahlen waren doch wieder ganz o.k. doch der Kurs fällt, nicht nachvollziehbar. Vielleicht kann man sich hier austauschen

Q3 2025 Earnings Snapshot** - **Adj EPS**: $1.30 (met est.) ✅ - **Revenue**: $11.37B (missed est. $11.4B) ❌; +6.9% YoY - **Organic Sales Growth**: +5.5% (+7.5% ex-COVID testing) **2025 Guidance (Reaffirmed)**: - Organic Sales Growth: 7.5-8.0% (ex-COVID); 6.0-7.0% (incl. COVID) - Adj EPS: $5.12-$5.18 (narrowed range) **Q3 Metrics**: - Reported Operating Margin: 18.1% - Adj Operating Margin: 23.0% (+40 bps YoY) - U.S. Sales: $4.30B (+2.3% YoY) - International Sales: $7.07B (+9.9% YoY) **Segment Performance**: - **Nutrition**: $2.15B (+4.2% reported, +4.0% organic) - Pediatric: $977M (+2.3% reported) - Adult: $1.18B (+5.8% reported) - **Diagnostics**: $2.25B (-6.6% reported, +0.4% organic ex-COVID) - COVID-19 Testing: $69M (vs. $265M Q3'24) - Core Lab: $1.36B (+3.8% reported) - Rapid Diagnostics: $600M (-27.3% reported) - **Established Pharma**: $1.51B (+7.5% reported, +7.1% organic) - **Medical Devices**: $5.45B (+14.8% reported, +12.5% organic) - Diabetes Care: $2.06B (+19.3% reported) - CGM Sales: $2.0B (+20.5% reported) - Electrophysiology: $705M (+15.6% reported) **CEO Robert Ford**: "Q3 reflects consistent, high-quality results driven by our strong product pipeline, ensuring durable value for shareholders."

$ABT | Abbott Labs Q2 2025 Earnings - Net Sales $11.14B (est $11.06B) - Adj EPS $1.26 (est $1.25) - Organic Sales +6.9% (est +7.03%) - Sees Q3 Adj EPS $1.28 To $1.32 (est $1.34) - Sees FY Adj EPS $5.10 To $5.20, Saw $5.05 To $5.25

$ABT | Abbott Labs Q1 2025 Earnings - Adj EPS $1.09 (est $1.07) - Net Sales $10.36B (est $10.4B) - Reaffirms FY Guidance - Still Sees FY Adj EPS $5.05 To $5.25 (est $5.15) - Sees Q2 Adj EPS $1.23 To $1.27 (est $1.25)

Aus meiner Sicht Ausbruch nach oben, nach längerer Seitwärtsphase

🥳🚀😂

Abbott Labs reports robust Q4 & 2024 results: $11B Q4 sales (+7.2%), $42B full-year (+4.6%). Strong organic growth in base business. 2025 outlook positive with 7.5-8.5% organic sales growth projected. 404th consecutive quarterly dividend declared

ABBOTT, RECKITT NOT LIABLE IN TRIAL OVER CLAIMS THAT PREMATURE INFANT FORMULA CAUSED DEBILITATING ILLNESS, JURY FINDS

Abbott Laboratories reported Q3 revenues of $10.63 billion: a +5% Y/Y growth and ~1% above consensus estimates. 🔹Operating margin expanded 0.51 p.p. Y/Y to 23.4%, roughly in line with the 23.4% expectation. 🔹EPS (non-GAAP) was $1.21: a +6% Y/Y increase, and 1% above consensus estimates.

#Abbott Laboratories $ABT #Earnings: - Q3 Non-GAAP EPS of $1.21 beats by $0.01. - Revenue of $10.64B (+4.9% Y/Y) beats by $90M.